Biochem/physiol Actions

PF-06672131 is a selective EGFR kinase inhibitor thought to covalently react with active-site cysteine residues in the ATP binding pocket. PF-06672131 has been used as a probe for proteomic analysis to identify off-target binding substrates. The dimethylaminomethyl (DMAM) group appears to increase compound stability in cancer cells with a resultant increase in protein reactivity from selective EGFR binding to widespread proteome-wide reactivity after treatment.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle